Progressive multifocal leukoencephalopathy

Handbook of Clinical Neurology

Volumn 123, Issue , 2014, Pages 357-376

  Berger, Joseph R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

AIDS; Demyelination; HIV; JC virus; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

NATALIZUMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BRAIN; DEMYELINATION; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; JC VIRUS; NEUROIMAGING; PATHOGENICITY; PATHOLOGY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIROLOGY;

AIDS; DEMYELINATION; HIV; JC VIRUS; NATALIZUMAB; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

BRAIN; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; NEUROIMAGING;

EID: 84903956943     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53488-0.00017-1     Document Type: Chapter

References (213)

1. Ahmed S., Rappaport J., Tada H., et al. A nuclear protein derived from brain cells stimulates transcription of the human neurotropic virus promoter, JCVE, in vitro. J Biol Chem 1990, 265:13899-13905.
2. Aksamit A., Proper J. JC virus replicates in primary adult astrocytes in culture. Ann Neurol 1988, 24:471.
3. Albrecht H., Hoffmann C., Degen O., et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. Aids 1998, 12:1149-1154.
4. Amemiya K., Traub R., Durham L., et al. Interaction of a nuclear factor-1-like protein with the regulatory region of the human polyomavirus JC virus. J Biol Chem 1989, 264:7025-7032.
5. Amemiya K., Traub R., Durham L., et al. Adjacent nuclear factor-1 and activator protein binding sites in the enhancer of the neurotropic JC virus. A common characteristic of many brain-specific genes. J Biol Chem 1992, 267:14204-14211.
6. Amend K.L., Turnbull B., Foskett N., et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010, 75:1326-1332.
7. Andrei G., Snoeck R., Vandeputte M., et al. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997, 41:587-593.
8. Antinori A., Ammassari A., Giancola M.L., et al. Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol 2001, 7:323-328.
9. Antinori A., Cingolani A., Lorenzini P., et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003, 9(Suppl 1):47-53.
10. Arbusow V., Strupp M., Pfister H.W., et al. Contrast enhancement in progressive multifocal leukoencephalopathy: a predictive factor for long-term survival? [letter]. J Neurol 2000, 247:306-308.
11. Arthur R.R., Dagostin S., Shah K.V. Detection of BK virus and JC virus in urine and brain tissue by the polymerase chain reaction. J Clin Microbiol 1989, 27:1174-1179.
12. Astrom K.E., Mancall E.L., Richardson E.P., et al. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease. Brain 1958, 81:93-111.
13. Bacellar H., Munoz A., Miller E.N., et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994, 44:1892-1900.
14. Baril L., Jouan M., Agher R., et al. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS. AIDS 2000, 14:2593-2596.
15. Bauer W.R., Turel A.P., Johnson K.P. Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. JAMA 1973, 226:174-176.
16. Bechtel M., Sanders C., Bechtel A. Neurological complications of biologic therapy in psoriasis: a review. J Clin Aesthet Dermatol 2009, 2:27-32.
17. Bedri J., Weinstein W., DeGregorio P., et al. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome. N Engl J Med 1983, 309:492-493.
18. Berger J.R. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol 2003, 9(Suppl 1):38-41.
19. Berger J.R. Steroids for PML-IRIS. A double-edged sword?. Neurology 2009, 72:1454-1455.
20. Berger J.R. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010, 33:969-983.
21. Berger J.R., Koralnik I.J. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N Engl J Med 2005, 353:414-416.
22. Berger J.R., Kaszovitz B., Post M.J., et al. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med 1987, 107:78-87.
23. Berger J., Pall L., McArthur J., et al. A pilot study of recombinant alpha 2a interferon in the treatment of AIDS-related progressive multifocal leukoencephalopathy (abstract). Neurology 1992, 42(Suppl 3):257.
24. Berger J.R., Scott G., Albrecht J., et al. Progressive multifocal leukoencephalopathy in HIV-1-infected children. AIDS 1992, 6:837-841.
25. Berger J.R., Levy R.M., Flomenhoft D., et al. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 1998, 44:341-349.
26. Berger J.R., Pall L., Lanska D., et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998, 4:59-68.
27. Berger J.R., Miller C., Mootoor Y., et al. Are Saliva and Oropharyngeal Secretions a Source of JCV Infection? 2005.
28. Berger J.R., Miller C.S., Mootoor Y., et al. JC virus detection in bodily fluids: Clues to transmission. Clin Infect Dis 2006, 43:e9-e12.
29. Bhigjee A.I., Patel V.B., Bhagwan B., et al. HIV and acute disseminated encephalomyelitis [letter]. S Afr Med J 1999, 89:283-284.
30. Tysabri update 2010, December 2, BiogenIdec, Retrieved January 14, 2011, from. https://medinfo.biogenidec.com.
31. Blick G., Whiteside M., Griegor P., et al. Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside [see comments]. Clin Infect Dis 1998, 26:191-192.
32. Brambilla A.M., Castagna A., Novati R., et al. Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy [letter]. J Neurol 1999, 246:723-725.
33. Brickelmaier M., Lugovskoy A., Kartikeyan R., et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 2009, 53:1840-1849.
34. Brochet B., Dousset V. Pathological correlates of magnetization transfer imaging abnormalities in animal models and humans with multiple sclerosis. Neurology 1999, 53:S12-S17.
35. Brooks B.R., Walker D.L. Progressive multifocal leukoencephalopathy. Neurol Clin 1984, 2:299-313.
36. Caldarelli-Stefano R., Vago L., Omodeo-Zorini E., et al. Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals. J Neurovirol 1999, 5:125-133.
37. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
38. Cavanaugh J., Greenbaum D., Marshall A., et al. Cerebral dymyelination associated with disorders of the reticuloendothelial system. Lancet 1959, 2:524-529.
39. Chang L., Ernst T., Tornatore C., et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997, 48:836-845.
40. Chapagain M.L., Sumibcay L., Gurjav U., et al. Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol 2008, 14:448-454.
41. Chetty K.G., Kim R.C., Mahutte C.K. Acute hemorrhagic leukoencephalitis during treatment for disseminated tuberculosis in a patient with AIDS. Int J Tuberc Lung Dis 1997, 1:579-581.
42. Christensen K.L., Holman R.C., Hammett T.A., et al. Progressive multifocal leukoencephalopathy deaths in the USA, 1979-2005. Neuroepidemiology 2010, 35:178-184.
43. Church J.A. Reversible leukoencephalopathy in a patient with nucleoside analogue-associated mitochondrial DNA depletion and metabolic disease. Aids 2002, 16:2366-2367.
44. Cinque P., Pierotti C., Vigano M.G., et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001, 7:358-363.
45. Cinque P., Bossolasco S., Brambilla A.M., et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003, 9(Suppl 1):73-80.
46. Clifford D.B., Yiannoutsos C., Glicksman M., et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999, 52:623-625.
47. Clifford D.B., De Luca A., Simpson D.M., et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9:438-446.
48. Conomy J., Beard N., Matsumoto H., et al. Cytarabine treatment of progressive multifocal leukoencephalopathy. JAMA 1974, 229:1313-1316.
49. Conway B., Halliday W.C., Brunham R.C., et al. Human immunodeficiency virus-associated progressive multifocal leukoencephalopathy: apparent response to 3'-azido-3'-deoxythymidine. Rev Infect Dis 1990, 12:479-482.
50. d'Arminio Monforte A., Duca P.G., Vago L., et al. Decreasing incidence of CNS AIDS-defining events associated with antiretroviral therapy. Neurology 2000, 54:1856-1859.
51. De Luca A., Ammassari A., Cingolani A., et al. Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy [letter]. Aids 1998, 12:1937-1938.
52. De Luca A., Fantoni M., Tartaglione T., et al. Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 1999, 52:891-892.
53. De Luca A., Giancola M.L., Ammassari A., et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 2000, 182:1077-1083.
54. Di Giambenedetto S., Vago G., Pompucci A., et al. Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?. Neurology 2004, 63:2452-2453.
55. Dodge R.T. A case study: the use of cidofovir for the management of progressive multifocal leukoencephalopathy. J Assoc Nurses AIDS Care 1999, 10:70-74.
56. Dorries K. Progressive multifocal leucoencephalopathy: analysis of JC virus DNA from brain and kidney tissue. Virus Res 1984, 1:25-38.
57. Drews K., Bashir T., Dorries K., et al. Quantification of human polyomavirus JC in brain tissue and cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy by competitive PCR. J Virol Methods 2000, 84:23-36.
58. Du Pasquier R.A., Koralnik I.J. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?. J Neurovirol 2003, 9(Suppl 1):25-31.
59. Du Pasquier R.A., Clark K.W., Smith P.S., et al. JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy. J Neurovirol 2001, 7:318-322.
60. Dugan A.S., Gasparovic M.L., Atwood W.J. Direct correlation between sialic acid binding and infection of cells by two human polyomaviruses (JC virus and BK virus). J Virol 2008, 82:2560-2564.
61. Elovaara I., Iivanainen M., Valle S.L., et al. CSF protein and cellular profiles in various stages of HIV infection related to neurological manifestations. J Neurol Sci 1987, 78:331-342.
62. Elphick G.F., Querbes W., Jordan J.A., et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004, 306:1380-1383.
63. Engsig F.N., Hansen A.B., Omland L.H., et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009, 199:77-83.
64. Fedele C.G., Ciardi M.R., Delia S., et al. Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. J Neurovirol 2003, 9:551-558.
65. Fong I.W., Britton C.B., Luinstra K.E., et al. Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Clin Microbiol 1995, 33:484-486.
66. Fox E.J. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother 2010, 10:1789-1797.
67. Frisque R.J., Martin J.D., Padgett B.L., et al. Infectivity of the DNA from four isolates of JC virus. J Virol 1979, 32:476-482.
68. Frisque R.J., Bream G.L., Cannella M.T., et al. Human polyomavirus JC virus genome. J Virol 1984, 51:458-469.
69. Gallamini A., Zaja F., Patti C., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316-2323.
70. Garcia-Suarez J., de Miguel D., Krsnik I., et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005, 80:271-281.
71. Gardner S.D., Field A.M., Coleman D.V., et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971, 1:1253-1257.
72. Geschwind M.D., Skolasky R.I., Royal W.S., et al. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 2001, 7:353-357.
73. Gheuens S., Pierone G., Peeters P., et al. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry 2010, 81:247-254.
74. Gillespie S.M., Chang Y., Lemp G., et al. Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981-1989. Ann Neurol 1991, 30:597-604.
75. Gofton T.E., Al-Khotani A., O'Farrell B., et al. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 2011, 82:452-455.
76. Goodman A., Goodman L., Rall T., et al. The pharmacological basis of therapeutics 1985, MacMillan, New York.
77. Gordon K.B., Papp K.A., Hamilton T.K., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003, 290:3073-3080.
78. Gorelik L., Lerner M., Bixler S., et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:295-303.
79. Gray F., Belec L., Lescs M.C., et al. Varicella-zoster virus infection of the central nervous system in the acquired immune deficiency syndrome. Brain 1994, 117:987-999.
80. Grinyo J., Charpentier B., Pestana J.M., et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010, 90:1521-1527.
81. Hall C.D., Dafni U., Simpson D., et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team [see comments]. N Engl J Med 1998, 338:1345-1351.
82. Helantera I., Koskinen P. Association of immune cell function assay with protocol biopsy findings and viral infections in well matched kidney transplant recipients. Clin Nephrol 2010, 74:123-131.
83. Henin D., Smith T.W., De Girolami U., et al. Neuropathology of the spinal cord in the acquired immunodeficiency syndrome. Hum Pathol 1992, 23:1106-1114.
84. Henson J., Saffer J., Furneaux H., et al. The transcription factor Sp1 binds to the JC virus promoter and is selectively expressed in glial cells in human brain. Ann Neurol 1992, 32:72-77.
85. Hoffmann C., Horst H.A., Albrecht H., et al. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003, 74:1142-1144.
86. Holman R.C., Janssen R.S., Buehler J.W., et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 1991, 41:1733-1736.
87. Holman R.C., Torok T.J., Belay E.D., et al. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology 1998, 17:303-309.
88. Hou J., Major E.O. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998, 4:451-456.
89. Houff S.A., Major E.O., Katz D.A., et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 1988, 318:301-305.
90. Huang S.S., Skolasky R.L., Dal Pan G.J., et al. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol 1998, 4:324-332.
91. Iacobaeus E., Ryschkewitsch C., Gravell M., et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009, 15:28-35.
92. Inui K., Miyagawa H., Sashihara J., et al. Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection. Brain Dev 1999, 21:416-419.
93. Iranzo A., Marti-Fabregas J., Domingo P., et al. Absence of thallium-201 brain uptake in progressive multifocal leukoencephalopathy in AIDS patients. Acta Neurol Scand 1999, 100:102-105.
94. Kalayjian R.C., Cohen M.L., Bonomo R.A., et al. Cytomegalovirus ventriculoencephalitis in AIDS. A syndrome with distinct clinical and pathologic features. Medicine (Baltimore) 1993, 72:67-77.
95. Kast R.E., Focosi D., Petrini M., et al. Treatment schedules for 5-HT2A blocking in progressive multifocal leukoencephalopathy using risperidone or ziprasidone. Bone Marrow Transplant 2007, 39:811-812.
96. Kastrup O., Wanke I., Esser S., et al. Evolution of purely infratentorial PML under HAART-negative outcome under rapid immune reconstitution. Clin Neurol Neurosurg 2005, 107:509-513.
97. Katz R.L., Alappattu C., Glass J.P., et al. Cerebrospinal fluid manifestations of the neurologic complications of human immunodeficiency virus infection. Acta Cytol 1989, 33:233-244.
98. Kerr D.A., Chang C.F., Gordon J., et al. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 1993, 196:612-618.
99. Khalili K., Rappaport J., Khoury G. Nuclear factors in human brain cells bind specifically to the JCV regulatory region. Embo J 1988, 7:1205-1210.
100. Khanna N., Elzi L., Mueller N.J., et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009, 48:1459-1466.
101. Kishida S., Tanaka K. Mefloquine treatment in a patient suffering from progressive multifocal leukoencephalopathy after umbilical cord blood transplant. Intern Med 2010, 49:2509-2513.
102. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369-374.
103. Knowles W.A., Pipkin P., Andrews N., et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003, 71:115-123.
104. Koralnik I.J. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol 2002, 8(Suppl 2):59-65.
105. Koralnik I.J., Du Pasquier R.A., Kuroda M.J., et al. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy. J Virol 2001, 75:3483-3487.
106. Koralnik I.J., Wuthrich C., Dang X., et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005, 57:576-580.
107. Krumbholz M., Meinl I., Hohlfeld R., et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008, 71:1350-1354.
108. Krupp L.B., Lipton R.B., Swerdlow M.L., et al. Progressive multifocal leukoencephalopathy: clinical and radiographic features. Ann Neurol 1985, 17:344-349.
109. Kuchelmeister K., Gullotta F., Bergmann M., et al. Progressive multifocal leukoencephalopathy (PML) in the acquired immunodeficiency syndrome (AIDS). A neuropathological autopsy study of 21 cases. Pathol Res Pract 1993, 189:163-173.
110. Kure K., Llena J.F., Lyman W.D., et al. Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. Hum Pathol 1991, 22:700-710.
111. Lang W., Miklossy J., Deruaz J.P., et al. Neuropathology of the acquired immune deficiency syndrome (AIDS): a report of 135 consecutive autopsy cases from Switzerland. Acta Neuropathol 1989, 77:379-390.
112. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375-381.
113. Lebwohl M., Tyring S.K., Hamilton T.K., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349:2004-2013.
114. Leonardi C.L. "Current concepts and review of efalizumab in the treatment of psoriasis". Dermatol Clin 2004, 22:427-435. ix.
115. Lidman C., Lindqvist L., Mathiesen T., et al. Progressive multifocal leukoencephalopathy in AIDS. Aids 1991, 5:1039-1041.
116. Lindberg R.L., Achtnichts L., Hoffmann F., et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008, 194:153-164.
117. London W.T., Houff S.A., Madden D.L., et al. Brain tumors in owl monkeys inoculated with a human polyomavirus (JC virus). Science 1978, 201:1246-1249.
118. Lynch K.J., Frisque R.J. Identification of critical elements within the JC virus DNA replication origin. J Virol 1990, 64:5812-5822.
119. Lynch K.J., Frisque R.J. Factors contributing to the restricted DNA replicating activity of JC virus. Virology 1991, 180:306-317.
120. Major E.O., Amemiya K., Elder G., et al. Glial cells of the human developing brain and B cells of the immune system share a common DNA binding factor for recognition of the regulatory sequences of the human polyomavirus, JCV. J Neurosci Res 1990, 27:461-471.
121. Major E.O., Amemiya K., Tornatore C.S., et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992, 5:49-73.
122. Marra C.M., Rajicic N., Barker D.E., et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS 2002, 16:1791-1797.
123. Marshall D.W., Brey R.L., Cahill W.T., et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988, 45:954-958.
124. Martin J.D., King D.M., Slauch J.M., et al. Differences in regulatory sequences of naturally occurring JC virus variants. J Virol 1985, 53:306-311.
125. Martin S.I., Marty F.M., Fiumara K., et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006, 43:16-24.
126. Maschke M., Kastrup O., Esser S., et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000, 69:376-380.
127. Matos A., Duque V., Beato S., et al. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 2010, 82:494-504.
128. Mazlo M., Herndon R. Progressive multifocal leukoencephalopathy: ultrastructural findings in two brain biopsies. Neuropathol Appl Neurobiol 1977, 3:323-339.
129. Mazlo M., Tariska I. Are astrocytes infected in progressive multifocal leukoencephalopathy (PML)?. Acta Neuropathol 1982, 56:45-51.
130. McGuire D., Barhite S., Hollander H., et al. JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy [published erratum appears in Ann Neurol 1995 May;37(5):687]. Ann Neurol 1995, 37:395-399.
131. Mengelle C., Kamar N., Mansuy J.M., et al. JC virus DNA in the peripheral blood of renal transplant patients: a 1-year prospective follow-up in France. J Med Virol 2011, 83:132-136.
132. Messite J., Stellman S.D. Accuracy of death certificate completion: the need for formalized physician training. JAMA 1996, 275:794-796.
133. Meylan P.R., Vuadens P., Maeder P., et al. Monitoring the response of AIDS-related progressive multifocal leukoencephalopathy to HAART and cidofovir by PCR for JC virus DNA in the CSF. Eur Neurol 1999, 41:172-174.
134. Miller J.R., Barrett R.E., Britton C.B., et al. Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982, 307:1436-1438.
135. Miller R.F., Lucas S.B., Hall-Craggs M.A., et al. Comparison of magnetic resonance imaging with neuropathological findings in the diagnosis of HIV and CMV associated CNS disease in AIDS. J Neurol Neurosurg Psychiatry 1997, 62:346-351.
136. Miralles P., Berenguer J., Garcia de Viedma, et al. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 1998, 12:2467-2472.
137. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009, 60:3761-3765.
138. Monaco M.C., Jensen P.N., Hou J., et al. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 1998, 72:9918-9923.
139. Morriss M.C., Rutstein R.M., Rudy B., et al. Progressive multifocal leukoencephalopathy in an HIV-infected child. Neuroradiology 1997, 39:142-144.
140. Neff R.T., Hurst F.P., Falta E.M., et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008, 86:1474-1478.
141. Nelson P.K., Masters L.T., Zagzag D., et al. Angiographic abnormalities in progressive multifocal leukoencephalopathy: an explanation based on neuropathologic findings. AJNR Am J Neuroradiol 1999, 20:487-494.
142. Neumann F., Zohren F., Haas R., et al. The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 2009, 9:1099-1106.
143. Nived O., Bengtsson A.A., Jonsen A., et al. Progressive multifocal leukoencephalopathy - the importance of early diagnosis illustrated in four cases. Lupus 2008, 17:1036-1041.
144. Nukuzuma S., Nakamichi K., Nukuzuma C., et al. Inhibitory effect of serotonin antagonists on JC virus propagation in a carrier culture of human neuroblastoma cells. Microbiol Immunol 2009, 53:496-501.
145. Omerud L., Rhodes R., Gross S.A., et al. Ophthalmologic manifestations of acquired immune deficiency syndrome-associated progressive multifocal leukoencephalopathy. Ophthalmology 1996, 103:899-906.
146. O'Reilly S. Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet 1997, 350:291.
147. O'Riordan T., Daly P., Hutchinson M., et al. Progressive multifocal leukoencephalopathy - remission with cytarabine. J Infect Dis 1990, 20:51-54.
148. Padgett B.L., Walker D.L. Virologic and serologic studies of progressive multifocal leukoencephalopathy. Prog Clin Biol Res 1983, 105:107-117.
149. Padgett B.L., Walker D.L., ZuRhein G.M., et al. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971, 1:1257-1260.
150. Pho M.T., Ashok A., Atwood W.J., et al. JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 2000, 74:2288-2292.
151. Port J.D., Miseljic S., Lee R.R., et al. Progressive multifocal leukoencephalopathy demonstrating contrast enhancement on MRI and uptake of thallium-201: a case report. Neuroradiology 1999, 41:895-898.
152. Post M.J., Yiannoutsos C., Simpson D., et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 1999, 20:1896-1906.
153. Querbes W., Benmerah A., Tosoni D., et al. A JC virus-induced signal is required for infection of glial cells by a clathrin- and eps15-dependent pathway. J Virol 2004, 78:250-256.
154. Rand K.H., Johnson K.P., Rubinstein L.J., et al. Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Ann Neurol 1977, 1:458-462.
155. Richardson E.J. Progressive multifocal leukoencephalopathy. Handbook of Clinical Neurology 1970, Vol. 9:485-499. Elsevier, New York.
156. Richardson E.P. Our evolving understanding of progressive multifocal leukoencephalopatha. Ann N Y Acad Sci 1974, 230:358-364.
157. Rossi A., Delbue S., Mazziotti R., et al. Presence, quantitation and characterization of JC virus in the urine of Italian immunocompetent subjects. J Med Virol 2007, 79:408-412.
158. Rudick R.A., O'Connor P.W., Polman C.H., et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010, 68:304-310.
159. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 2002, 8(Suppl 2):115-121.
160. Sadler M., Chinn R., Healy J., et al. New treatments for progressive multifocal leukoencephalopathy in HIV-1-infected patients. AIDS 1998, 12:533-535.
161. Safdar A., Rubocki R.J., Horvath J.A., et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002, 35:1250-1257.
162. Samorei I.W., Schmid M., Pawlita M., et al. High sensitivity detection of JC-virus DNA in postmortem brain tissue by in situ PCR. J Neurovirol 2000, 6:61-74.
163. Satishchandra P., Nalini A., Gourie-Devi M., et al. Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96). Indian J Med Res 2000, 111:14-23.
164. Scaravilli F., Daniel S.E., Harcourt-Webster N., et al. Chronic basal meningitis and vasculitis in acquired immunodeficiency syndrome. A possible role for human immunodeficiency virus [see comments]. Arch Pathol Lab Med 1989, 113:192-195.
165. Schroder A., Lee D.H., Hellwig K., et al. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010, 67:1391-1394.
166. Selik R.M., Karon J.M., Ward J.W. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997, 176:632-636.
167. Silverman L., Rubinstein L.J. Electron microscopic observations on a case of progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl) 1965, 5:215-224.
168. Singer C., Berger J.R., Bowen B.C., et al. Akinetic-rigid syndrome in a 13-year-old girl with HIV-related progressive multifocal leukoencephalopathy. Mov Disord 1993, 8:113-116.
169. Sparano J.A., Anand K., Desai J., et al. Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Immune Defic Syndr 1999, 21(Suppl 1):S18-S22.
170. Steiger M.J., Tarnesby G., Gabe S., et al. Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol 1993, 33:407-411.
171. Stoner G., Ryschkewitsch C. Evidence of JC virus in two progressive multifocal leukoencephalopathy (PML) brains previously reported to be infected with SC40. J Neuropathol Exp Neurol 1991, 50:342.
172. Sweeney B.J., Manji H., Miller R.F., et al. Cortical and subcortical JC virus infection: two unusual cases of AIDS associated progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 1994, 57:994-997.
173. Tada H., Lashgari M., Rappaport J., et al. Cell type-specific expression of JC virus early promoter is determined by positive and negative regulation. J Virol 1989, 63:463-466.
174. Taguchi F., Kajioka J., Miyamura T. Prevalence rate and age of acquisition of antibodies against JC virus and BK virus in human sera. Microbiol Immunol 1982, 26:1057-1064.
175. Tamura T., Inoue T., Nagata K., et al. Enhancer of human polyoma JC virus contains nuclear factor I-binding sequences; analysis using mouse brain nuclear extracts. Biochem Biophys Res Commun 1988, 157:419-425.
176. Tan K., Roda R., Ostrow L., et al. PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 2009, 72:1458-1464.
177. Tan C.S., Ellis L.C., Wuthrich C., et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol 2010, 84:9200-9209.
178. Tantisiriwat W., Tebas P., Clifford D.B., et al. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 1999, 28:1152-1154.
179. Taoufik Y., Gasnault J., Karaterki A., et al. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 1998, 178:1816-1820.
180. Tashiro K., Doi S., Moriwaka F., et al. Progressive multifocal leucoencephalopathy with magnetic resonance imaging verification and therapeutic trials with interferon. J Neurol 1987, 234:427-429.
181. Thurnher M.M., Post M.J., Rieger A., et al. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol 2001, 22:977-984.
182. Tominaga T., Yogo Y., Kitamura T., et al. Persistence of archetypal JC virus DNA in normal renal tissue derived from tumor-bearing patients. Virology 1992, 186:736-741.
183. Tooze J. Human papovaviruses. Molecular biology of tumor viruses, vol. 2. DNA Tumor Viruses 1980, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. J. Tooze (Ed.).
184. Tornatore C., Berger J., Winfield D., et al. Detection of JC viral genome in the lymphocytes of non-PML HIV positive patients: association with B cell lymphopenia. Neurology 1992, 42(Suppl 3):211.
185. Tornatore C., Berger J.R., Houff S.A., et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 1992, 31:454-462.
186. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
187. Van Horn G., Bastian F., Moake J. Progressive multifocal leukoencephalopathy: failure of response to transfer factor and cytarabine. Neurology 1978, 28:794-797.
188. Verbraak F.D., Boom R., Wertheim-van Dillen P.M., et al. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease. Br J Ophthalmol 1999, 83:1186-1189.
189. Verma S., Cikurel K., Koralnik I.J., et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 2007, 196:709-711.
190. Vidal J.E., Penalva de Oliveira A.C., Fink M.C., et al. Aids-related progressive multifocal leukoencephalopathy: a retrospective study in a referral center in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo 2008, 50:209-212.
191. Vollmer-Haase J., Young P., Ringelstein E.B. Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet 1997, 349:1366.
192. von Einsiedel R.W., Fife T.D., Aksamit A.J., et al. Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature. J Neurol 1993, 240:391-406.
193. Waggoner J., Martinu T., Palmer S.M. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 2009, 28:395-398.
194. Walker D., Padgett B. The epidemiology of human polyomaviruses. Polyomaviruses and human neurological disease 1983, 99-106. Alan R. Liss, New York. J. Sever, D. Madden (Eds.).
195. Walker D., Padgett B. Progressive multifocal leukoencephalopathy. Comprehensive virology 1983, 161-193. Plenum, New York. H. Fraenkel-Conrat, R. Wagner (Eds.).
196. Walker D.L., Padgett B.L., ZuRhein G.M., et al. Human papovavirus (JC): induction of brain tumors in hamsters. Science 1973, 181:674-676.
197. Warnke C., Smolianov V., Dehmel T., et al. "CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus". Mult Scler 2011, 17:151-156.
198. Weber T., Turner R., Ruf B., et al. JC virus detected by polymerase chain reaction in cerebrospinal fluid of AIDS patients with progressive multifocal leukoencephalopathy. Neurological and neuropsychological complications of HIV infection. Proceedings from the Satellite Meeting of the International Conference on AIDS 1990.
199. Weber T., Turner R.W., Frye S., et al. Progressive multifocal leukoencephalopathy diagnosed by amplification of JC virus-specific DNA from cerebrospinal fluid. AIDS 1994, 8:49-57.
200. Weber F., Goldmann C., Kramer M., et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 2001, 49:636-642.
201. Whiteman M.L., Post M.J., Berger J.R., et al. Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation. Radiology 1993, 187:233-240.
202. Wolinsky J.S., Johnson K.P., Rand K., et al. Progressive multifocal leukoencephalopathy: clinical pathological correlates and failure of a drug trial in two patients. Trans Am Neurol Assoc 1976, 101:81-82.
203. Wong M.C., Suite N.D., Labar D.R. Seizures in human immunodeficiency virus infection. Arch Neurol 1990, 47:640-642.
204. Wroblewska Z., Wellish M., Bilden D. Growth of JC virus in adult human brain cell cultures. Arch Virol 1980, 65:141-148.
205. Wuthrich C., Dang X., Westmoreland S., et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009, 65:742-748.
206. Wyen C., Hoffmann C., Schmeisser N., et al. Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death. J Acquir Immune Defic Syndr 2004, 37:1263-1268.
207. Yamamura T. Molecular target drug development for curing multiple sclerosis. Brain Nerve 2009, 61:923-928.
208. Yiannoutsos C.T., Major E.O., Curfman B., et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 1999, 45:816-821.
209. Yogo T., Kitamura T., Sugimoto C., et al. Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals. J Virol 1990, 64:3139-3143.
210. Yogo Y., Kitamura T., Sugimoto C., et al. Sequence rearrangement in JC virus DNAs molecularly cloned from immunosuppressed renal transplant patients. J Virol 1991, 65:2422-2428.
211. Zaheer F., Berger J. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Safety 2012, 3:227-239.
212. ZuRhein G. Particles resembling papovavirions in human cerebral demyelinating disease. Science 1965, 148:1477-1479.
213. ZuRhein G. Polyona-like virions in a human demyelinating disease. Acta Neuro Pathol (Berl) 1967, 8:57-68.